AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29461363 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mm Hg capsule pressure
Number of subjects: 30
Study 26043861 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 servings (96 g) of WG wheat
Number of subjects: 19
Study 26043861 — intervention group
Group type: COMPARATOR
Intervention: 3 servings (48 g) of WG wheat
Number of subjects: 19
Study 25461966 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) used as an adjunct to endodontic re-treatment
Number of subjects: 21
Study 25461966 — intervention group
Group type: COMPARATOR
Intervention: Endodontic re-treatment alone
Number of subjects: 21
Study 22366285 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial exercise
Number of subjects: 12
Study 22366285 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted exercise
Number of subjects: 12
Study 22366285 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 19771507 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly strength training
Number of subjects: 234
Study 19771507 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 234
Study 18382132 — intervention group
Group type: EXPERIMENTAL
Intervention: Stamaril
Number of subjects: 2514
Study 18382132 — intervention group
Group type: EXPERIMENTAL
Intervention: VCFA
Number of subjects: 2514
Study 15823450 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC (50/100 microg)
Number of subjects: 18
Study 15823450 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 microg)
Number of subjects: 18
Study 15823450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19753741 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdermabrasion treatments (six sessions of aluminum oxide microdermabrasion spaced over 7 to 10-day intervals)
Number of subjects: 11
Study 19753741 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdermabrasion treatments (six sessions)
Number of subjects: 11
Study 10369157 — intervention group
Group type: EXPERIMENTAL
Intervention: Flashbackers
Number of subjects: 87
Study 10369157 — intervention group
Group type: COMPARATOR
Intervention: Non-flashbackers
Number of subjects: 87
Study 10369157 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 87
Study 7553254 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (2 x 2.5 mg/d for 14 days)
Number of subjects: 150
Study 7553254 — intervention group
Group type: EXPERIMENTAL
Intervention: Metergoline (3 x 4 mg/d for 10 days)
Number of subjects: 150
Study 7553254 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding subjects (control group)
Number of subjects: 150
Study 2045463 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 40
Study 2045463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7000139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent sunlamps (B)
Number of subjects: 40
Study 7000139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent UV‐A lamps (A + B)
Number of subjects: 40
Study 7000139 — intervention group
Group type: EXPERIMENTAL
Intervention: Germicidal lamps (A + B + C)
Number of subjects: 40
Study 7000139 — intervention group
Group type: EXPERIMENTAL
Intervention: Photochemotherapy with oral 8‐MOP followed by UV‐A (PUVA)
Number of subjects: 40
Study 7000139 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule followed by A + B (pUVAB)
Number of subjects: 40
Study 7000139 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no light
Number of subjects: 40
Study 30471456 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided microforceps (TTNB)
Number of subjects: 114
Study 30471456 — intervention group
Group type: COMPARATOR
Intervention: EUS-guided fine-needle aspiration (FNA)
Number of subjects: 114
Study 27787472 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 22
Study 27787472 — intervention group
Group type: COMPARATOR
Intervention: Control (non-exercising)
Number of subjects: 22
Study 25321886 — intervention group
Group type: EXPERIMENTAL
Intervention: Teen Options for Change (TOC)
Number of subjects: 49
Study 25321886 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (Control)
Number of subjects: 49
Study 24203541 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoelectrically controlled functional electrical stimulation (MeCFES)
Number of subjects: 11
Study 24203541 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study 21425515 — intervention group
Group type: EXPERIMENTAL
Intervention: Pajunk Sonoplex (echogenic) needle
Number of subjects: 60
Study 21425515 — intervention group
Group type: COMPARATOR
Intervention: Pajunk Uniplex (control) needle
Number of subjects: 60
Study 20024850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic heart disease (IHD) with hypertension
Number of subjects: 160
Study 20024850 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 160
Study 17392352 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab dose escalation (1.5 mg/kg increments)
Number of subjects: 329
Study 17392352 — intervention group
Group type: COMPARATOR
Intervention: Infliximab 3 mg/kg
Number of subjects: 329
Study 17392352 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab dose escalation(s)
Number of subjects: 329
Study 15466998 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients (n=46)
Number of subjects: 46
Study 15466998 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic controls (n=50)
Number of subjects: 46
Study 11137922 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasonography (DU)
Number of subjects: 89
Study 11137922 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 89
Study 9875038 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin K1 (Konakion MM) - 2 mg at birth, repeated at 7 and 30 days
Number of subjects: 156
Study 9875038 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vitamin K1 - 1 mg
Number of subjects: 156
Study 8040759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy with an external insulin pump or at least three daily insulin injections, together with frequent daily blood-glucose monitoring
Number of subjects: 195
Study 8040759 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy with one or two daily insulin injections and once-daily monitoring
Number of subjects: 195
Study 2723103 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine mouthrinse (20 ml, twice daily for 6 months)
Number of subjects: 107
Study 2723103 — intervention group
Group type: COMPARATOR
Intervention: Hydroalcohol control
Number of subjects: 107
Study 780039 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol sulfate (10 to 20 mg, four times daily for 180 days)
Number of subjects: 25
Study 780039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31434541 — intervention group
Group type: EXPERIMENTAL
Intervention: MEN Count intervention
Number of subjects: 454
Study 31434541 — intervention group
Group type: COMPARATOR
Intervention: Attention comparison condition focused on stress reduction
Number of subjects: 454
Study 28615007 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-centred music making (RMM) intervention, 10 weekly sessions
Number of subjects: 54
Study 25205061 — intervention group
Group type: EXPERIMENTAL
Intervention: Uneventful small incision cataract surgery (SICS)
Number of subjects: 200
Study 25205061 — intervention group
Group type: COMPARATOR
Intervention: Uneventful phacoemulsification
Number of subjects: 200
Study 22951047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node resection (SNR)
Number of subjects: 744
Study 22951047 — intervention group
Group type: COMPARATOR
Intervention: Axillary dissection (AD)
Number of subjects: 744
Study 22951047 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 744
Study 21859932 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kg azithromycin extended-release (ER)
Number of subjects: 38
Study 21859932 — intervention group
Group type: COMPARATOR
Intervention: 30 mg/kg azithromycin immediate-release (IR)
Number of subjects: 38
Study 18049093 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐Flurodeoxyglucose positron emission tomography (FDG PET)
Number of subjects: 29
Study 18049093 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched and sex-matched subjects without neurological/psychiatric disease)
Number of subjects: 29
Study 17148533 — intervention group
Group type: EXPERIMENTAL
Intervention: Imputation methods (including last value carried forward, regression procedures, and simple mean)
Number of subjects: 0
Study 17148533 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete case analysis, imputation, and modelling procedures
Number of subjects: 0
Study 12829523 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated hypertensive group
Number of subjects: 1249
Study 12829523 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated hypertensive group
Number of subjects: 1249
Study 12829523 — intervention group
Group type: COMPARATOR
Intervention: Normotensive group
Number of subjects: 1249
Study 12829523 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 1249
Study 12829523 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical groups comparison
Number of subjects: 1249
Study 12829523 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated hypertensive group vs Untreated hypertensive group
Number of subjects: 1249
Study 10687982 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal examination and transrectal ultrasonography at PSA 0 to 4.0 ng/ml
Number of subjects: 9211
Study 10687982 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA 2 to 4 ng/ml
Number of subjects: 9211
Study 10687982 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA 0 to 4 ng/ml
Number of subjects: 9211
Study 9322122 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cytokeratin 19 levels > 2 ng/mL in pancreatic duct cell carcinoma
Number of subjects: 123
Study 9322122 — intervention group
Group type: COMPARATOR
Intervention: Serum cytokeratin 19 levels in chronic pancreatitis
Number of subjects: 123
Study 9322122 — intervention group
Group type: COMPARATOR
Intervention: Serum cytokeratin 19 levels in islet cell tumors
Number of subjects: 123
Study 9322122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity of cytokeratin 19 assay
Number of subjects: 123
Study 9322122 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical expression of cytokeratin 19
Number of subjects: 123
Study 8195846 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodimoprim
Number of subjects: 2291
Study 8195846 — intervention group
Group type: COMPARATOR
Intervention: Comparative agents (ampicillin, amoxicillin, cephalosporins, erythromycin, doxycycline, chloramphenicol)
Number of subjects: 2291
Study 3026016 — intervention group
Group type: EXPERIMENTAL
Intervention: sulbactam/ampicillin (50 mg/kg per day, intravenous bolus injection at 6-hr intervals for four to 11 days, mean duration 9 days)
Number of subjects: 23
Study 3026016 — intervention group
Group type: EXPERIMENTAL
Intervention: sulbactam/penicillin (1:1.2 or 1:1.8 ratio, intravenous bolus injection at 6-hr intervals for four to 11 days, mean duration 9 days)
Number of subjects: 23
Study 30676382 — intervention group
Group type: EXPERIMENTAL
Intervention: IV-PCA enhanced with ketorolac/diclofenac
Number of subjects: 143
Study 30676382 — intervention group
Group type: COMPARATOR
Intervention: TEA
Number of subjects: 143
Study 30676382 — intervention group
Group type: EXPERIMENTAL
Intervention: IV-PCA
Number of subjects: 143
Study 29169916 — intervention group
Group type: EXPERIMENTAL
Intervention: Lissamine green solution (GreenGlo)
Number of subjects: 0
Study 29169916 — intervention group
Group type: EXPERIMENTAL
Intervention: Lissamine green solution (Lissaver)
Number of subjects: 0
Study 29169916 — intervention group
Group type: EXPERIMENTAL
Intervention: OPGreen solution
Number of subjects: 0
Study 29169916 — intervention group
Group type: EXPERIMENTAL
Intervention: Single versus double drop instillation
Number of subjects: 0
Study 29169916 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated lid evertion
Number of subjects: 0
Study 26783292 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5% nicotine electronic cigarette
Number of subjects: 99
Study 26783292 — intervention group
Group type: COMPARATOR
Intervention: Placebo electronic cigarette
Number of subjects: 99
Study 25002661 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐CS+Bisacodyl
Number of subjects: 299
Study 25002661 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐Asc
Number of subjects: 299
Study 25002661 — intervention group
Group type: EXPERIMENTAL
Intervention: NaPico+MgCit
Number of subjects: 299
Study 25002661 — intervention group
Group type: COMPARATOR
Intervention: PEG‐ELS
Number of subjects: 299
Study 22834681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (30 ml)
Number of subjects: 42
Study 22834681 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 42
Study 21163117 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 825 mg/m² twice daily plus weekly docetaxel 30 mg/m² on days 1 and 8 every 21 days
Number of subjects: 41
Study 17481878 — intervention group
Group type: EXPERIMENTAL
Intervention: RTube
Number of subjects: 23
Study 17481878 — intervention group
Group type: EXPERIMENTAL
Intervention: EcoScreen
Number of subjects: 23
Study 17481878 — intervention group
Group type: COMPARATOR
Intervention: Storage for 8 weeks
Number of subjects: 23
Study 15928658 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 500 mg m(‐2) b.i.d.(‐1)
Number of subjects: 204
Study 15928658 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 625 mg m(‐2) b.i.d.(‐1)
Number of subjects: 204
Study 15928658 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin, Cisplatin, 5-Fluorouracil (ECF)
Number of subjects: 204
Study 15928658 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin, Oxaliplatin, 5-Fluorouracil (EOF)
Number of subjects: 204
Study 15928658 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin, Cisplatin, Capecitabine (ECX)
Number of subjects: 204
Study 15928658 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin, Oxaliplatin, Capecitabine (EOX)
Number of subjects: 204
Study 15928658 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (F)
Number of subjects: 204
Study 15497659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant 10 mg/day
Number of subjects: 112
Study 15497659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant 15 mg/day
Number of subjects: 112
Study 15497659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant 20 mg/day
Number of subjects: 112
Study 15497659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant
Number of subjects: 112
Study 15497659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 10571718 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed educational brochure
Number of subjects: 740
Study 10571718 — intervention group
Group type: COMPARATOR
Intervention: Postcard reminder
Number of subjects: 740
Study 8737522 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboembolism prophylaxis with acenocoumarol during radiation therapy
Number of subjects: 0
Study 8737522 — intervention group
Group type: EXPERIMENTAL
Intervention: LMW heparin during radiation therapy
Number of subjects: 0
Study 8737522 — intervention group
Group type: COMPARATOR
Intervention: Acenocoumarol during radiation therapy
Number of subjects: 0
Study 2065389 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of phentolamine (20‐30 mg/day) and angelicini (150‐450 mg/day)
Number of subjects: 60
Study 2065389 — intervention group
Group type: COMPARATOR
Intervention: Conventional supporting therapy
Number of subjects: 60
Study 6760236 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxy vitamin D3
Number of subjects: 23
Study 6760236 — intervention group
Group type: COMPARATOR
Intervention: 24,25-dihydroxy vitamin D3
Number of subjects: 23
Study 6760236 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitution of 1,25-dihydroxy vitamin D3 for 24,25-dihydroxy vitamin D3
Number of subjects: 23
Study 6760236 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful renal transplantation
Number of subjects: 23
Study 31576438 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia during CPB (inspired fraction of oxygen of one to one)
Number of subjects: 330
Study 31576438 — intervention group
Group type: COMPARATOR
Intervention: Standard care (oxygen to achieve partial arterial blood pressure less than 150 mmHg)
Number of subjects: 330
Study 31576438 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia during CPB
Number of subjects: 330
Study 31576438 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 330
Study 30684340 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin
Number of subjects: 84
Study 25892654 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training combined with heavy strength training (E+S)
Number of subjects: 19
Study 25892654 — intervention group
Group type: COMPARATOR
Intervention: Normal endurance training only (E)
Number of subjects: 19
Study 23721658 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of primary health care workers in mental health using a specially designed toolkit
Number of subjects: 3437
Study 23721658 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no training)
Number of subjects: 3437
Study 22818729 — intervention group
Group type: EXPERIMENTAL
Intervention: Variety of vegetables (200 g of each of broccoli, carrots, and snap peas)
Number of subjects: 66
Study 22818729 — intervention group
Group type: COMPARATOR
Intervention: Single vegetable servings (600 g of broccoli, carrots, or snap peas)
Number of subjects: 66
Study 20558324 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Ventricular Apex (RVA)
Number of subjects: 33
Study 20558324 — intervention group
Group type: COMPARATOR
Intervention: Right Ventricular Outflow Tract (RVOT)
Number of subjects: 33
Study 17437242 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum interleukin‐6 (IL‐6)
Number of subjects: 47
Study 17437242 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum interleukin‐1β (IL‐1β)
Number of subjects: 47
Study 17437242 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitive C‐reactive protein (CRP)
Number of subjects: 47
Study 17437242 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal blood samples with histologic chorioamnionitis
Number of subjects: 47
Study 17437242 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal blood samples with connatal infection
Number of subjects: 47
Study 17437242 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal blood samples with periventricular leukomalacia (PVL)
Number of subjects: 47
Study 17437242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancies with preterm premature rupture of membranes (PPROM)
Number of subjects: 47
Study 16260697 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ + IFN-alpha
Number of subjects: 294
Study 16260697 — intervention group
Group type: COMPARATOR
Intervention: TMZ alone
Number of subjects: 294
Study 12149599 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (2 x 50 mg)
Number of subjects: 17
Study 12149599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 10215302 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic estrogen replacement therapy
Number of subjects: 122
Study 7793735 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg IV over 30 minutes, followed by 1 mg/kg/hr infusion for 12 hours)
Number of subjects: 30
Study 7793735 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline of equal volume)
Number of subjects: 30
Study 2323324 — intervention group
Group type: EXPERIMENTAL
Intervention: High-choice decisional control manipulation
Number of subjects: 0
Study 2323324 — intervention group
Group type: COMPARATOR
Intervention: Low-choice decisional control manipulation
Number of subjects: 0
Study 2323324 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management and action instructions (given to all students)
Number of subjects: 0
Study 2323324 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported work orientation
Number of subjects: 0
Study 43338 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine hydrochloride
Number of subjects: 10
Study 43338 — intervention group
Group type: COMPARATOR
Intervention: Thiothixene
Number of subjects: 10
Study 43338 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 10
Study 43338 — intervention group
Group type: COMPARATOR
Intervention: Thioridazine
Number of subjects: 10
Study 43338 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 10
Study 31280967 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (150 mg subcutaneously at weeks 0 and 4)
Number of subjects: 605
Study 31280967 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (80 mg subcutaneously at randomisation, then 40 mg at weeks 1, 3, 5, and every other week thereafter)
Number of subjects: 605
Study 31280967 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (40 mg)
Number of subjects: 605
Study 31280967 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (150 mg)
Number of subjects: 605
Study 31280967 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported in risankizumab group
Number of subjects: 605
Study 31280967 — intervention group
Group type: COMPARATOR
Intervention: Adverse events reported in adalimumab group
Number of subjects: 605
Study 31280967 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported in risankizumab group (part B)
Number of subjects: 605
Study 31280967 — intervention group
Group type: COMPARATOR
Intervention: Adverse events reported in adalimumab group (part B)
Number of subjects: 605
Study 29798119 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep apnea monitoring management platform
Number of subjects: 48
Study 29798119 — intervention group
Group type: COMPARATOR
Intervention: Traditional CPAP card reader mode
Number of subjects: 48
Study 29798119 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48